Rapid activation of the alternative pathway of complement by extracorporeal membrane oxygenation

ASAIO J. 1999 Jan-Feb;45(1):113-4. doi: 10.1097/00002480-199901000-00025.

Abstract

Extracorporeal membrane oxygenation (ECMO) is an effective therapy for patients with severe respiratory distress syndromes. However, an inflammatory response has been observed with the use of this therapy. We measured complement activation in vivo in two adults receiving ECMO for acute respiratory distress syndrome (ARDS). Production of complement activation fragments C4d, Bb, iC3b, and SC5b-9 was determined using commercial ELISA kits. In both patients there was intense activation of complement that peaked 1 hour (mean SC5b-9 increase to 1135% of baseline) after the start of ECMO and occurred predominantly via the alternative pathway (Bb production). Early and acute complement activation may be responsible for the initiation of the inflammatory response that has been observed in patients treated with ECMO.

Publication types

  • Case Reports
  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood
  • Complement Activation*
  • Complement C3b / analysis
  • Complement C4 / analysis
  • Complement C4b*
  • Enzyme-Linked Immunosorbent Assay
  • Extracorporeal Membrane Oxygenation / adverse effects*
  • Fatal Outcome
  • Female
  • Humans
  • Inflammation / immunology*
  • Male
  • Middle Aged
  • Peptide Fragments / analysis
  • Peptide Fragments / blood*
  • Respiratory Distress Syndrome / immunology
  • Respiratory Distress Syndrome / therapy

Substances

  • Biomarkers
  • Complement C4
  • Peptide Fragments
  • Complement C3b
  • Complement C4b
  • complement C4d